Home | This Week's Contents  |  C&EN ClassifiedsSearch C&EN Online

Related Stories
Amgen To Buy Rival Immunex
[C&EN, Dec. 24, 2001]

Drug Deal-Making Dynamics Change
[C&EN, Jan. 28, 2002]

Fighting The Clock
[C&EN, Jan. 28, 2002]

Turning Point For Biopharmaceuticals
[C&EN, July 31, 2000]

Related Sites




E-mail this article to a friend
Print this article
E-mail the editor
 Table of Contents
 C&EN Classifieds
 News of the Week
 Cover Story
 Editor's Page
 Government & Policy
  Government & Policy
 ACS News
 Digital Briefs
 ACS Comments
 Career & Employment
 Special Reports
 What's That Stuff?
 Pharmaceutical Century

 Hot Articles
 Safety  Letters

 Back Issues

 How to Subscribe
 Subscription Changes
 About C&EN
 Copyright Permission
 E-mail webmaster
April 22, 2002
Volume 80, Number 16
CENEAR 80 16 p. 7
ISSN 0009-2347
[Previous Story] [Next Story]

Biotech Leaders Ally In Manufacturing Pact


Genentech will produce Immunex' antirheumatoid arthritis drug Enbrel under a manufacturing agreement signed last week. Sales of the drug have been limited by a supply shortage caused by strong demand and lack of manufacturing capacity.

Immunex, which is in the process of being acquired by Amgen, expects sales of Enbrel, among the top-selling biopharmaceuticals, to hit $1 billion this year, up from $762 million in 2001.

Immunex has already acquired from Wyeth a facility in Rhode Island dedicated to Enbrel production. Wyeth also markets the drug through its pharmaceuticals division. Immunex expects to obtain FDA approval for the plant in the second half of 2002.

The Genentech agreement is a longer term solution to the capacity problem. FDA approval for production by Genentech is not expected until 2004, when its facility in South San Francisco will become a licensed manufacturing plant for the drug. Peggy V. Phillips, executive vice president and chief operating officer at Immunex, says, "This Genentech agreement adds flexibility and depth to our plans to expand the production capacity of Enbrel to the multi-billion-dollar level."

Immunex' latest move underscores a point made in a study of biological manufacturing capacity by analysts at U.S. Bancorp Piper Jaffray. They found that, given current investments, there will be ample capacity for biologics manufacturing as new plants become functional over the next five years. But some biotech companies will face capacity shortfalls in the intervening years as they struggle to match supply with industry demand.

[Previous Story] [Next Story]


Chemical & Engineering News
Copyright © 2002 American Chemical Society

Home | Table of Contents | News of the Week | Cover Story
Business | Government & Policy | Science/Technology
Chemical & Engineering News
Copyright © 2002 American Chemical Society - All Right Reserved
1155 16th Street NW • Washington DC 20036 • (202) 872-4600 • (800) 227-5558

CASChemPortChemCenterPubs Page